The monoclonal antibody cocktail developed by Regeneron and made well-known by POTUS during his stay at Walter Reed Medical Center has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA). Initially called REGN-COV-2 and also...
REGN-COV2
Category
Christus St. Frances Cabrini Health System Offers COVID-19 At Risk Patients REGN-COV2 via Compassionate Use
CHRISTUS St. Frances Cabrini Health System (Christus Cabrini) is one of the first health centers in Louisiana to offer the investigational monoclonal antibody developed by Regeneron known as REGN-COV2 to treat mild-to-moderate SARS-CoV-2 (COVID-19). This particular...
IDMC Observes Some Safety Signals in Regeneron’s Study of REGN-COV2 in Hospitalized Patients: Recommendations Made to Modify
Regeneron’s monoclonal antibody investigational product known as REGN-COV2 has been touted by trial site’s all over the United States, almost in a marketing like manner due to the explicit promotion of the drug by POTUS during the stay at Walter Reed Medical Center....
Atrium Health Helps Pave Path Toward Clinical Research as a Care Option Targeting COVID-19 with Three New Clinical Trials Offering Outpatient Hope
Atrium Health, formerly the Carolinas HealthCare System, has been active on multiple fronts battling COVID-19. The nonprofit network of over 40 hospitals and over 900 care locations in North Carolina, South Carolina, and Georgia have also emerged as a leading player...
Is REGN-COV2 Developed Using Cell Line From Aborted Fetus? Catholic Ethicists Split on the Use of Attenuated Fetal Tissue
Sometime before 1973, a woman in Holland had an abortion. Her fetus, a female, was donated for scientific use. A cell from the fetus’s kidney has “lived” ever since, with a cell line grown from it used widely in medical research and the production of biologics such as...
Regeneron Submits Request for FDA EUA for REGN-COV2 in Head to Head Competition with Eli Lilly
Regeneron reported that subsequent to the New York-based company’s discussions with regulatory authorities, they have submitted a request to the U.S. Food and Drug Administration for an Emergency Use Authorization (EUA) for their investigational REGN-COV2...
Investigational Products ‘Coming Down from God’—POTUS, Promotion & Trial Site Operations
President Trump’s (POTUS) brief hospital stay and introduction to investigational therapies targeted for COVID-19, such as the advanced monoclonal antibody cocktail called REGN-COV2 from Regeneron, has certainly fixated the media and possibly contributed to clinical...
Is President Donald Trump Participating in the REGN-COV2 Trial?
Reports are that President Donald Trump is participating in the REGN-COV2 clinical trial involving Regeneron’s cocktail monoclonal antibody product. Apparently, physician Sean Conley released a statement that POTUS received a single 8 gram dose of REGN-COV2 after his...
REGN-COV2 Data Looks Quite Promising But More Investigation Ahead
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the first data from a descriptive analysis of a seamless Phase 1/2/3 trial of its investigational antibody cocktail REGN-COV2 showing it reduced viral load and the time to alleviate symptoms in...
University of Tennessee Health Science Center, Memphis Conducts REGN-COV2 Study
Dr. John Jefferies, professor and chief of Cardiology at The University of Tennessee Health Science Center (UTHSC), suggested recently on local media that Regeneron’s monoclonal antibody cocktail called REGN-COV2 could potentially be a “game changer” in treating...
Trial Site Operation in San Antonio Reports Positive Momentum for Regeneron Monoclonal Antibody REGN-COV-2
TrialSite has reported that Lilly's monoclonal antibody (LY-CoV555) evidenced promise at a trial site location in southern Texas and that shortly thereafter recent interim analysis data from Lilly backed that observation. Now Regeneron’s monoclonal antibody cocktail...
MemorialCare Long Beach Medical Center Initiates REGN-COV2 Monoclonal Antibody Study Targeting COVID-19
MemorialCare Long Beach Medical Center will participate in two multinational clinical trials investigating the efficacy and safety of two different anti-viral treatments designed to reduce the severity as well as possibly halt the spread of COVID-19 in both...
Oxford RECOVERY Trial Investigates Regeneron’s REGN-COV2: Will it Reduce Mortality, Hospital Stay & Need for Ventilation?
The prominent global RECOVERY (Randomized Evaluation of COVid-19 thERapY) is one of the world’s largest randomized clinical trials of potential COVID-19 treatments. It was this study that discovered the benefit of dexamethasone in severe COVID-19 cases. The University...
Sioux Falls-based Avera Health Joins REGN-COV2 Clinical Trials Investigating Powerful Monoclonal Antibodies Targeting COVID-19
Regeneron has selected a Sioux Falls-based health care system called Avera Health as a Phase 2 and 3 trial site for the ongoing lab-produced monoclonal antibody combination, known as REGN-COV2, targeting COVID-19. Avera Health, a fully integrated health system...
Sarasota Memorial Hospital Leads Advanced Monoclonal Antibody Clinical Trial for Investigational Product Called REGN-COV2
Sarasota Hospital has joined Regeneron’s investigation into testing whether the experimental antibody cocktail called REGN-COV2 can prevent infection by SARS-CoV-2, the virus behind COVID-19. One of approximately 100 trial site organizations around the nation,...
Roche Inks Deal with Regeneron to Develop and Distribute REGN-COV2 Worldwide, Should the Monoclonal Antibody Cocktail be Approved
Roche teamed up with Regeneron to co-develop, manufacture and distribute REGN-COV2, the investigational advanced antibody combination designed and developed by Regeneron to target COVID-19. The collaboration is sought to increase the supply of REGN-COV2 for worldwide...
Oxnard, CA’s FOMAT Medical Research Secures Two Big Clinical Trials with Regeneron Investigating REGN-COV2
Although perhaps not a household name among big pharmaceutical sponsors perhaps that may change as FOMAT Medical Research in Oxnard, California, recently secured a major contract with Regeneron to participate in their highly watched, Operation Warp Speed-funded...
UC Davis Selected to Participate in the REGN-COV2 Clinical Trial Investigating Monoclonal Antibody Targeting COVID-19
UC Davis Health investigators, thanks to a recent federal grant, are preparing to test a promising new antibody cocktail, known as REGN-COV2, as a prevention and treatment for SARS-CoV-2, the virus behind COVID-19. Led by Dr. Timothy Albertson, chairman of internal...
East Coast Institute for Research Takes on REGN-COV2 Phase 3 Clinical Trial for those Exposed to Someone with COVID-19
East Coast Institute for Research, a clinical investigational site in Jacksonville, Florida, will commence a novel clinical trial next week testing Regeneron’s REGN-COV2, the monoclonal antibody designed to target SARS-COV-2. The study will be led by Dr. Rebecca...
UW-Madison Selected for the Phase 3 Clinical Trial Investigating Monoclonal Antibody-based Cocktail Targeting COVID-19
The University of Wisconsin has been selected by Regeneron for the Phase 3 clinical trial evaluating REGN-COV2, the advanced investigational monoclonal antibody designed to destroy SARS-CoV-2, the virus behind COVID-19. This novel investigational product has been...